aluminium chloride
Burow invented an astringent antiseptic solution of aluminium acetate in water to relieve the itching and inflammation of minor skin irritations. At present the oflicial U. S. P. procedure to made Burow's solution involves the reaction of aluminum sulfate, calcium carbonate and acetic acid to form aluminum sub-acetate, also termed basic aluminum acetate. The solution is available as an over-the-counter drug for topical administration, with brand names including Domeboro. Burow's solution has been shown to be effective against chronic suppurative otitis media and otitis externa. It is active against bacteria resulting in damage to the cell wall. — NCATS
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Mar 31, 2016 (NCT03433859)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
SMILES
[Al+3]- Mol. weight
- 26.9815386 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAluminium chloride ↗
- NCATS3XHB1D032B ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05079217 | Phase 4 | Nov 1, 2021 | Government of China, Sinovac Biotech Co., Ltd |
| NCT03433859 | Phase 3 | Mar 31, 2016 | Direction Centrale du Service de Santé des Armées, Hôpital Clermont-Tonnerre |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Direction Centrale du Service de Santé des Armées | Government | 1 | 1 | 1 | 2016 |
| Government of China | Government | 1 | 0 | 1 | 2021 |
| Hôpital Clermont-Tonnerre | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Sinovac Biotech Co., Ltd | For profit | 1 | 1 | 1 | 2021 |